18
views
0
recommends
+1 Recommend
1 collections
    0
    shares

      Drug Design, Development and Therapy (submit here)

      This international, peer-reviewed Open Access journal by Dove Medical Press focuses on the design and development of drugs, as well as the clinical outcomes, patient safety, and programs targeted at the effective and safe use of medicines. Sign up for email alerts here.

      88,007 Monthly downloads/views I 4.319 Impact Factor I 6.6 CiteScore I 1.12 Source Normalized Impact per Paper (SNIP) I 0.784 Scimago Journal & Country Rank (SJR)

       

      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      The Inhibitory Effects of Juglanin on Adipogenesis in 3T3-L1 Adipocytes

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Introduction

          Deregulation of adipogenesis plays an important role in obesity and other metabolism disorders. PPAR, C/EBP and SREBP1c are key transcriptional factors involved in adipogenesis and lipogenesis. Juglanin is a natural compound belonging to flavonoids, and it has been reported that juglanin has a potent inhibitory effect on inflammation and certain type of cancers. However, the effects of juglanin in adipogenesis have not been reported before.

          Materials and Methods

          3T3-L1 preadipocytes were incubated with differentiation induction medium in the presence or absence of 0.5, 2.5, or 5 µM juglanin for an 8-day differentiation period. The lipid droplets accumulated in the cytoplasm were monitored by Oil Red O staining on days 0, 2, 5, and 8. The regulatory effects of juglanin on adipogenesis-related genes and proteins were investigated by real-time polymerase chain reaction and Western blot analysis.

          Results

          Juglanin significantly decreased lipid accumulation in differentiated adipocytes. Our findings show that juglanin reduced the expression of C/EBPα, C/EBPβ, and SREBP-1c without affecting PPARα or PPARγ expression. Additionally, juglanin increased the activation of the SIRT1/AMPK signaling pathway through the phosphorylation of AMPKα. Finally, we performed an AMPK inhibitor experiment, which revealed that the inhibitory effects of juglanin on adipogenesis are mediated through AMPK.

          Discussion

          Juglanin can prevent adipogenesis by suppressing lipid accumulation and the differentiation of preadipocytes. The mechanism of juglanin regulating adipogenesis requires further investigation. Future clinical study in vivo could shed more light on its implication in modulating obesity and metabolic disorders.

          Most cited references46

          • Record: found
          • Abstract: found
          • Article: not found

          SREBP-regulated lipid metabolism: convergent physiology — divergent pathophysiology

          In addition to controlling cellular lipid metabolism and homeostasis, sterol regulatory element-binding proteins (SREBPs) act as nodes of convergence and divergence within myriad physiological and pathophysiological processes. Here, Shimano and Sato provide a comprehensive overview of the role of SREBPs in health and disease, at the cell, organ and organism levels.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Prevalence of Obesity and Severe Obesity in US Children, 1999–2016

            To provide updated prevalence data on obesity trends among US children and adolescents aged 2 to 19 years from a nationally representative sample.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver.

              The earliest defect in developing type 2 diabetes is insulin resistance, characterized by decreased glucose transport and metabolism in muscle and adipocytes. The glucose transporter GLUT4 mediates insulin-stimulated glucose uptake in adipocytes and muscle by rapidly moving from intracellular storage sites to the plasma membrane. In insulin-resistant states such as obesity and type 2 diabetes, GLUT4 expression is decreased in adipose tissue but preserved in muscle. Because skeletal muscle is the main site of insulin-stimulated glucose uptake, the role of adipose tissue GLUT4 downregulation in the pathogenesis of insulin resistance and diabetes is unclear. To determine the role of adipose GLUT4 in glucose homeostasis, we used Cre/loxP DNA recombination to generate mice with adipose-selective reduction of GLUT4 (G4A-/-). Here we show that these mice have normal growth and adipose mass despite markedly impaired insulin-stimulated glucose uptake in adipocytes. Although GLUT4 expression is preserved in muscle, these mice develop insulin resistance in muscle and liver, manifested by decreased biological responses and impaired activation of phosphoinositide-3-OH kinase. G4A-/- mice develop glucose intolerance and hyperinsulinaemia. Thus, downregulation of GLUT4 and glucose transport selectively in adipose tissue can cause insulin resistance and thereby increase the risk of developing diabetes.
                Bookmark

                Author and article information

                Journal
                Drug Des Devel Ther
                Drug Des Devel Ther
                dddt
                dddt
                Drug Design, Development and Therapy
                Dove
                1177-8881
                02 December 2020
                2020
                : 14
                : 5349-5357
                Affiliations
                [1 ]Department of Intensive Care Unit, The First Hospital of Jilin University , Changchun, Jilin 130033, People’s Republic of China
                [2 ]Department of Neurosurgery, China-Japan Union Hospital of Jilin University , Changchun, Jilin 130033, People’s Republic of China
                [3 ]Department of Periodontology, School and Hospital of Stomatology, Jilin University , Changchun, Jilin 130033, People’s Republic of China
                [4 ]Department of Urology, China-Japan Union Hospital of Jilin University, Jilin Key Laboratory of Urologic Oncology , Changchun, Jilin 130033, People’s Republic of China
                [5 ]Department of Obstetrics and Gynecology, China-Japan Union Hospital of Jilin University , Changchun, Jilin 130033, People’s Republic of China
                [6 ]Department of Endocrinology and Metabolism, The First Hospital of Jilin University , Changchun, Jilin 130033, People’s Republic of China
                Author notes
                Correspondence: Heyuan Wang Department of Endocrinology and Metabolism, The First Hospital of Jilin University , Changchun, Jilin130033, People’s Republic of China Tel/Fax +86-431-88782222 Email wangheyuan220@163.com
                [*]

                These authors contributed equally to this work

                Article
                256504
                10.2147/DDDT.S256504
                7719332
                61fd922b-249c-4466-90ea-554f7b580192
                © 2020 Wang et al.

                This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.php).

                History
                : 01 April 2020
                : 23 September 2020
                Page count
                Figures: 8, References: 46, Pages: 9
                Categories
                Original Research

                Pharmacology & Pharmaceutical medicine
                juglanin,adipogenesis,obesity,lipid metabolism,ampk
                Pharmacology & Pharmaceutical medicine
                juglanin, adipogenesis, obesity, lipid metabolism, ampk

                Comments

                Comment on this article